AAAAAA
Results: 1-25/43
Authors:
Carrieri, P
Cailleton, V
Le Moing, V
Spire, B
Dellamonica, P
Bouvet, E
Raffi, F
Journot, V
Moatti, JP
Citation: P. Carrieri et al., The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort, J ACQ IMM D, 28(3), 2001, pp. 232-239
Authors:
Le Moing, V
Chene, G
Carrieri, MP
Besnier, JM
Masquelier, B
Salamon, R
Bazin, C
Moatti, JP
Raffi, F
Leport, C
Citation: V. Le Moing et al., Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors, J ACQ IMM D, 27(4), 2001, pp. 372-376
Authors:
Lewden, C
Raffi, F
Chene, G
Sobel, A
Leport, C
Citation: C. Lewden et al., Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy - Standardization to the general population, J ACQ IMM D, 26(5), 2001, pp. 480-482
Authors:
Hoff, J
Bani-Sadr, F
Gassin, M
Raffi, F
Citation: J. Hoff et al., Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens, CLIN INF D, 32(6), 2001, pp. 963-969
Authors:
Richard, P
Delangle, MH
Raffi, F
Espaze, E
Richet, H
Citation: P. Richard et al., Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora, CLIN INF D, 32(1), 2001, pp. 162-166
Authors:
Leautez, S
Boutoille, D
Renard, B
Esnault, JL
Raffi, F
Citation: S. Leautez et al., Pulmonary hypertension in HIV-infected patients, REV MAL RES, 18(4), 2001, pp. 432-435
Authors:
Reliquet, V
Robillard, N
Perre, P
Muller, JY
Raffi, F
Audrain, M
Citation: V. Reliquet et al., Immune response to antiretroviral treatment combining stavudine, didanosine and nevirapine, PRESSE MED, 30(23), 2001, pp. 1143-1147
Authors:
Cremieux, AC
Katlama, C
Gillotin, C
Demarles, D
Yuen, GJ
Raffi, F
Citation: Ac. Cremieux et al., A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, PHARMACOTHE, 21(4), 2001, pp. 424-430
Authors:
Staszewski, S
Keiser, P
Montaner, J
Raffi, F
Gathe, J
Brotas, V
Hicks, C
Hammer, SM
Cooper, D
Johnson, M
Tortell, S
Cutrell, A
Thorborn, D
Isaacs, R
Hetherington, S
Steel, H
Spreen, W
Citation: S. Staszewski et al., Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults - A randomized equivalence trial, J AM MED A, 285(9), 2001, pp. 1155-1163
Authors:
Michelet, C
Ruffault, A
Sebille, V
Arvieux, C
Jaccard, P
Raffi, F
Bazin, C
Chapplain, JM
Chauvin, JP
Dohin, E
Cartier, F
Bellissant, E
Citation: C. Michelet et al., Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients, ANTIM AG CH, 45(12), 2001, pp. 3393-3402
Authors:
Rabaud, C
Charreau, I
Izard, S
Raffi, F
Meiffredy, V
Leport, C
Guillemin, F
Yeni, P
Aboulker, JP
Citation: C. Rabaud et al., Adverse reactions to cotrimoxazole in HIV-infected patients: Predictive factors and subsequent HIV disease progression, SC J IN DIS, 33(10), 2001, pp. 759-764
Authors:
Le Moing, V
Chene, G
Masquelier, B
Sicard, D
Brun-Vezinet, F
Reynes, J
Raffi, F
Citation: V. Le Moing et al., Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy, J ACQ IMM D, 24(1), 2000, pp. 82-83
Authors:
Girard, PM
Pegram, PS
Diquet, B
Anderson, R
Raffi, F
Tubiana, R
Sereni, D
Boerner, D
Citation: Pm. Girard et al., Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection:Pharmacokinetics, tolerability, and efficacy, J ACQ IMM D, 23(3), 2000, pp. 227-235
Authors:
Raffi, F
Reliquet, V
Ferre, V
Arvieux, C
Hascoet, C
Bellein, V
Besnier, JM
Breuz, JP
Garre, M
May, T
Molina, JM
Perre, P
Raguin, G
Rozenbaum, W
Zucman, D
Citation: F. Raffi et al., The VIRGO Study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults, ANTIVIR TH, 5(4), 2000, pp. 267-272
Authors:
Piroth, L
Grappin, M
Cuzin, L
Mouton, Y
Bouchard, O
Raffi, F
Rey, D
Peyramond, D
Gourdon, F
Drobacheff, C
Lombart, ML
Lucht, F
Besnier, JM
Bernard, L
Chavanet, P
Portier, H
Citation: L. Piroth et al., Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients, J VIRAL HEP, 7(4), 2000, pp. 302-308
Authors:
Raffi, F
Bonnet, B
Ferre, V
Esnault, JL
Perre, P
Reliquet, V
Leautez, S
Bouillant, C
Vergnoux, O
Weinbreck, P
Citation: F. Raffi et al., Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA, CLIN INF D, 31(5), 2000, pp. 1274-1278
Authors:
Leautez, S
Boutoille, D
Bemer-Melchior, P
Ponge, T
Raffi, F
Citation: S. Leautez et al., Localized Mycobacterium genavense soft tissue infection in an immunodeficient HIV-negative patient, EUR J CL M, 19(1), 2000, pp. 51-52
Authors:
Boutoille, D
Leautez, S
Maulaz, D
Krempf, M
Raffi, F
Citation: D. Boutoille et al., The need for multidisciplinary management, PRESSE MED, 29(7), 2000, pp. 387-387
Authors:
Boutoille, D
Leautez, S
Maulaz, D
Krempf, M
Raffi, F
Citation: D. Boutoille et al., Skin bone and joint bacterial infections in the diabetic foot: Epidemiology and pathophysiology, PRESSE MED, 29(7), 2000, pp. 389-392
Authors:
Boutoille, D
Leautez, S
Maulaz, D
Krempf, M
Raffi, F
Citation: D. Boutoille et al., Skin bone and joint bacterial infections in the diabetic foot: Role of infection, PRESSE MED, 29(7), 2000, pp. 393-395
Authors:
Boutoille, D
Leautez, S
Maulaz, D
Krempf, M
Raffi, F
Citation: D. Boutoille et al., Skin bone and joint bacterial infections in the diabetic foot: Treatment, PRESSE MED, 29(7), 2000, pp. 396-400
Authors:
Bani-Sadr, F
Leautez, S
El Kouri, D
Hamidou, M
Barrier, JH
Raffi, F
Citation: F. Bani-sadr et al., Contribution of immunoglobulins in the treatment of Schulman's fasciitis, PRESSE MED, 29(6), 2000, pp. 307-307
Authors:
Raffi, F
Citation: F. Raffi, Switching from a protease inhibitor to a non-nucleosidic reverse transcriptase inhibitor: 18 months follow-up, PRESSE MED, 29(37), 2000, pp. 2036-2037
Authors:
Mary-Krause, M
Rabaud, C
Jouan, M
Obadia, M
de la Blanchardiere, A
Raffi, F
May, T
Citation: M. Mary-krause et al., Mycobacterium avium complex disease (MAC) in HIV patients: incidence and risk factors before and after HAART., PATH BIOL, 48(5), 2000, pp. 495-504
Authors:
Descamps, D
Flandre, P
Calvez, V
Peytavin, G
Meiffredy, V
Collin, G
Delaugerre, C
Robert-Delmas, S
Bazin, B
Aboulker, JP
Pialoux, G
Raffi, F
Brun-Vezinet, F
Citation: D. Descamps et al., Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy, J AM MED A, 283(2), 2000, pp. 205-211